Clinical Trials Browser

Breast Neoplasms × tucatinib × 90 days × Clear all

NCT06686394 2026-05-22

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07494448 2026-04-23

JAZMINE

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT05132582 2026-04-20

HER2CLIMB-05

Phase 3 Active not recruiting

Breast Neoplasms

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase 2 Recruiting

Breast Neoplasms

NCT04539938 2026-03-23

HER2CLIMB-04

Phase 2 Completed

70 enrolled 23 charts

Breast Neoplasms

NCT05748834 2026-03-20

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms